

North Central Cancer Treatment Group

N0821: A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age \geq 70 yrs) with Good Performance Status (PS $<$ 2)

Update 2 – June 18, 2010

Summary

Administrative/editorial updates.

Replacement pages are included. Please incorporate into the protocol and keep this update with your protocol.

Title page Updated to reflect Update 2 and current NCI version date.

Protocol Resources

Page 2: **Kristine M. Hacker, R.N.** has replaced Dianne M. Herrera, R.N. as NCCTG *Research Base Nurse*

Rachael Meyers has replaced ~~Sarah Hanson~~ as the NCCTG *Research Base Quality Assurance Specialist*.

Section 14.0 **Body Fluid Biospecimens**

Page 36: Shipping instructions have been updated as follows in Sections 14.251, 14.254, 14.255, and 14.256:

- 14.251 Verify ALL sections of the Blood Specimen Submission Form (Forms Packet), ~~MML~~ **Biospecimen Accessioning and Processing (BAP)** Requisition Form (provided in kit), and the specimen collection label is completed and filled in correctly...
- 14.254 Ship specimens via Priority Overnight service, Monday – Thursday ONLY, to ~~Mayo Medical Laboratories (MML)~~ **BAP**. Do not send samples on weekends or holidays.
- 14.255 The ~~MML~~ **BAP** kits will contain a smart shipper label affixed to the ~~berry-colored~~ shipping boxes or a pre-filled airbill will be provided. Shipping costs will be covered by NCCTG if these kits are used for shipping specimens to ~~MML~~ **BAP**.
- 14.256 ~~MML~~ **BAP receiving** will receive the samples and immediately forward specimens to the NCCTG Research Base Biospecimens Accessioning and Processing (BAP) Shared Resource, Stable 13-10A, Attention: BAP Supervisor.